Alphamab Oncology Presents JSKN003 Clinical Data at 2025 ASCO Annual Meeting
Alphamab Oncology (HKG: 9966) presented the latest clinical data for its drug candidate JSKN003 at...
ADC / XDC
MSD Presents Zilovertamab Vedotin Results at ASCO Annual Meeting
US-based Merck, Sharp & Dohme (MSD; NYSE: MRK) last week presented results from the dose...
CSPC Pharmaceutical in Advanced Talks for $5B Licensing Deals
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) revealed that it is currently in negotiations with...
Jiangsu Hengrui Secures NMPA Approvals for Trastuzumab Rezetecan, Famitinib and HR20013
China’s Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that it has received separate marketing...
Astellas Pharma Licenses Evopoint’s CLDN18.2 ADC for Global Development
Japan-based Astellas Pharma Inc. (TYO: 4503) has entered into a licensing agreement with China-headquartered Evopoint...
GSK’s Blenrep Recommended for EU Approval in Multiple Myeloma
UK-based pharmaceutical giant GlaxoSmithKline (GSK, NYSE: GSK) announced that its Blenrep (belantamab mafodotin) has been...
Kelun-Biotech’s Sacituzumab Tirumotecan Accepted for NMPA Review for HR+, HER2- Breast Cancer
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) announced that another indication approval filing for its...
Minghui Pharmaceutical Launches Phase II Study of Combination Therapy for Advanced NSCLC
China-based Minghui Pharmaceutical Inc. announced the initiation of a Phase II clinical study to evaluate...
GSK’s Blenrep Receives Marketing Approval in Japan for Multiple Myeloma
UK-based pharmaceutical giant GlaxoSmithKline (GSK, NYSE: GSK) announced that it has received marketing approval from...
Zai Lab’s ZL-1310 Receives FDA Fast Track Designation for SCLC
China-based biotech Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) announced that it has received Fast...
CSPC Pharmaceutical’s CPO301 Receives Third FDA Fast Track Designation for NSqNSCLC
China-based CSPC Pharmaceutical Group Limited (HKG: 1093) announced that its EGFR-targeted antibody-drug conjugate (ADC) CPO301...
Merck Sharp & Dohme Initiates Phase III Trial of Ifinatamab Deruxtecan for Esophageal Cancer
US-based Merck, Sharp & Dohme Inc. (MSD; NYSE: MRK) announced the first patient dosing in...
Medilink Therapeutics Gains FDA IND Approval for VEGF-Targeted ADC YL242
Suzhou-based Medilink Therapeutics announced that it has received Investigational New Drug (IND) approval from the...
RemeGen’s Disitamab Vedotin Phase III Study Meets PFS and OS Endpoints
China-based RemeGen Ltd (HKG: 9995) announced that its Phase III clinical study for the antibody...
Grand Pharma Completes Patient Enrollment for TLX591-CDx Phase III Trial
Grand Pharmaceutical Group Limited (HKG: 0512) announced the completion of patient enrollment for the Phase...
Minghui Pharmaceutical Signs Licensing Deal with Qilu for B7-H3 ADC Development
China-based Minghui Pharmaceutical has entered into an exclusive licensing and collaboration agreement with Qilu Pharmaceutical....
Shanghai Escugen Partners with ConjugateBio on EZWi-Fit Platform for ADC Development
China-based Shanghai Escugen has entered into an exclusive option agreement with US-headquartered ConjugateBio Inc. regarding...
RemeGen’s Disitamab Vedotin Receives NMPA Approval for HER2+ Breast Cancer with Liver Metastasis
China-based biopharma RemeGen Ltd (HKG: 9995) announced that the National Medical Products Administration (NMPA) has...
AstraZeneca and Daiichi Sankyo Announce Positive DESTINY-Breast11 Trial Results for Enhertu
Partners AstraZeneca (NASDAQ: AZN) and Daiichi Sankyo (TYO: 4568) announced the positive preliminary results from...
Grand Pharma Receives NMPA Review for Phase III Trial of TLX591 in Prostate Cancer
China-based Grand Pharmaceutical Group Limited (HKG: 0512) announced that a filing to conduct a Phase...